Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Methotrexate (Primary) ; Regorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Nov 2019 Planned End Date changed from 1 Jun 2020 to 1 Mar 2021.
- 20 Nov 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Jan 2021.
- 20 Nov 2019 Status changed from suspended to recruiting.